Statins and clinical outcome of acute ischemic stroke: a systematic review

Table 2 Study design and odds ratio

Study	Study design	# of patients	Follow up period	OR, 95% CI, P value	Measures
Martí-Fàbregas 2004 [14]	cohort	167	3 months	OR = 5.55; 95% CI = 1.42- 17.8; P = 0.012	Favorable outcome (NIHSS, mRS ≤ 2, BI)
Yoon 2004 [15]	observational	436	2 years	OR = 2.9; 95% CI = 1.2-6.7, P = 0.03	Favorable outcome (mRS ≤ 2)
Greisenegger 2004 [16]	cohort	1691	1 week	OR = 0.37; 95% CI = 0.19- 0.74; P = 0.004	Poor stroke outcome (mRS of 5 or 6)
Moonis 2005 [17]	cohort	852	12 weeks	OR = 1.57; 95% CI = 1.04-2.38; P = 0.033	Favorable outcome (mRS ≤ 2)
Reeves 2008 [18]	cohort	1360	6 months	OR 0.74, 95% CI = 0.52-1.02	Poor stroke outcome (mRS ≥ 4 at discharge)
Stead 2009 [20]	cohort	508	22 months	OR = 1.91; 95% CI = 1.05- 3.47	Favorable outcome (NIHSS, mRS ≤ 2)
Goldstein 2009 [21]	Exploratory analysis of SPARCL trial data	576	3 months	N/A	Favorable outcome (NIHSS, mRS)

mRS, modified Rankin Scale; N/A, not available; NIHSS, National Institutes of Health Stroke Scale. OR, Odds Ratio; CI, Confidence Interval